Coxibs and cardiovascular disease.
Fitzgerald
Garret A
GA
Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, USA.
D016907:Adverse Drug Reaction Reporting Systems; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000494:pharmacology; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D000068579:Celecoxib; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000494:pharmacology; D017277:Drug Approval; D004345:Drug Industry; D011464:Epoprostenol / Q000037:antagonists & inhibitors; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000378:metabolism; D007555:Isoxazoles / Q000009:adverse effects; D007783:Lactones / Q000009:adverse effects* / Q000494:pharmacology; D008565:Membrane Proteins; D009288:Naproxen / Q000009:adverse effects; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D011720:Pyrazoles; D012306:Risk; D013449:Sulfonamides / Q000009:adverse effects / Q000494:pharmacology; D013450:Sulfones; D013928:Thromboxane A2 / Q000096:biosynthesis; D014481:United States; D014486:United States Food and Drug Administration; D000096926:Benzenesulfonamides
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000068579:Celecoxib; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D011464:Epoprostenol; D007527:Isoenzymes; D007555:Isoxazoles; D007783:Lactones; D008565:Membrane Proteins; D009288:Naproxen; D011451:Prostaglandin-Endoperoxide Synthases; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; D013928:Thromboxane A2; C116926:rofecoxib; C406224:valdecoxib; D000096926:Benzenesulfonamides; C496540:PTGS2 protein, human